Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bayer AG is conducting a first-in-human clinical study titled ‘First-in-human Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-CCR8 Antibody BAY 3375968 as Monotherapy and in Combination With Pembrolizumab in Participants With Selected Advanced Solid Tumors.’ The study aims to assess the safety and optimal dosing of BAY3375968, both alone and combined with pembrolizumab, in treating advanced solid tumors that have shown resistance to current immunotherapies.
The study is testing BAY3375968, an anti-CCR8 antibody, which targets regulatory T cells to enhance the immune response against cancer. This intervention is being evaluated alone and in combination with pembrolizumab, a PD-1 inhibitor, to determine its efficacy and safety in treating various advanced solid tumors.
This interventional study follows a non-randomized, sequential model without masking. It is primarily focused on treatment, with the first phase involving dose escalation to find the optimal dose, followed by a dose expansion phase targeting specific cancer types.
The study began on October 11, 2022, with an estimated completion date set for June 26, 2025. These timelines are crucial for tracking the progress and potential market entry of the treatment.
The update on this study could influence Bayer’s stock performance by showcasing its commitment to innovative cancer treatments, potentially boosting investor confidence. The study’s outcome may also impact the competitive landscape in oncology, particularly concerning immunotherapy advancements.
The study is currently ongoing, with further details accessible on the ClinicalTrials portal.